Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania. Show more
Location: 3805 Old Easton Road, Doylestown, PA, 18902, United States | Website: https://aprea.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
9.569M
52 Wk Range
$1.41 - $5.01
Previous Close
$1.77
Open
$1.76
Volume
63,117
Day Range
$1.60 - $1.86
Enterprise Value
-8.617M
Cash
19.28M
Avg Qtr Burn
-3.313M
Insider Ownership
11.91%
Institutional Own.
40.94%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ATRN-119 Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
APR-1051 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
Eprenetapopt (APR-246) + azacitidine Details Acute myeloid leukemia, Cancer, Myelodysplastic syndrome | Failed Discontinued | |
APR-548 + azacitidine Details Mutant Myelodysplastic Syndromes | Failed Discontinued | |
Eprenetapopt (APR-246) + Azacitidine Details Blood disorder, Myelodysplastic syndrome | Failed Discontinued |